Pharmakologische in-vitro-Inhibition von humanen Linsenepithelzellen zur Prävention der Cataracta secundaria

In der modernen Kataraktchirurgie ist die Cataracta secundaria nach wie vor die häufigste Komplikation in den ersten 5 Jahren postoperativ. Ziel war es, die pharmakologische Wirkung des T-Kalziumkanal-Antagonisten Mibefradil auf die In-vitro-Inhibition von humanen Linsenepithelzellen zur Prävention der Cataracta secundaria zu untersuchen. Die Synthese eines Wirkstoffbeladenen Polymers und dessen chemische Ankopplung an die Kapselspannringoberfläche führte zu einer signifikanten Beeinträchtigung der Zelladhäsion und der Zellproliferation

Prevention of Lens Epithelial Cell Growth In Vitro Using Mibefradil-Containing PLGA Micro Particles

The prevention of the posterior capsule opacification is still unsolved. To interfere with proliferating cells the T-type calcium channel antagonist Mibefradil was immobilized in poly-lactic-co-glycolic-acid micro particles which were fixed at a capsular tension ring and tested in a human organ culture model as well as in human lens cells HLE-B3 in vitro. It is feasible to get a release significantly affecting cell viability and growth evaluated by MTT test and cell cycle analysis. In addition, Bionas® sensor chips were used for time-dependent adhesion experiments in living lens cells. Interestingly, the concentration of Mibefradil which inhibited subconfluent cells is not effective in confluent cells. This is an important feature for the protection of the intact tissue in the eye